スマートバイオ（業績集）
2024
5. Tanaka T, Suzuki H, Ohishi T, Kaneko MK, Kato Y.
A Cancer-Specific anti-Podoplanin Monoclonal Antibody, PMab-117-mG2a Exerted Antitumor Activities in Human Tumor Xenograft Models
Cells, 13(22), 1833; https://doi.org/10.3390/cells13221833, 2024 (PDF; preprint)
4. Hirose M, Suzuki H, Ubukata R, Tanaka T, Kaneko MK, Kato Y.
Development of specific anti-mouse atypical chemokine receptor 4 monoclonal antibodies
Biochem Biophys Rep, 40, 101824, https://doi.org/10.1016/j.bbrep.2024.101824, 2024 (PDF; preprint)
3. Ishikawa K, Suzuki H, Ohishi T, Nakamura T, Yanaka M, Li G, Tanaka T, Kawada M, Kaneko MK, Ohkoshi A, Katori Y, Kato Y.
Antitumor activities of defucosylated anti-CD44 monoclonal antibodies in mouse xenograft models of esophageal cancer
Oncology reports, 52(5), 147, https://doi.org/10.3892/or.2024.8806, (PDF; preprint)
2. Ishikawa K, Suzuki H, Ohishi T, Li G, Tanaka T, Kawada M, Ohkoshi A, Kaneko MK, Katori Y, Kato Y.
Anti-CD44 variant 10 monoclonal antibody exerts antitumor activity in mouse xenograft models of oral squamous cell carcinomas
Int. J. Mol. Sci., 25(17), 9190; https://doi.org/10.3390/ijms25179190, 2024 (PDF; preprint)
1. Suzuki H, Ohishi T, Tanaka T, Kaneko MK, Kato Y.
Anti‐HER2 cancer‐specific mAb, H2Mab‐250‐hG1 possesses higher complement‐dependent cytotoxicity than trastuzumab
Int. J. Mol. Sci., 25(15), 8386; https://doi.org/10.3390/ijms25158386, 2024 (PDF; preprint)
業績
AMED project
動画(YouTube)
参考文献(pdf)
